1. Apo-B48 in patients with type 2 diabetes and non-alkoholic fatty liver disease. (September 2016) Authors: Idzior-Waluś, B.; Walus-Miarka, M.; Trojak, A.; Miarka, P.; Kapusta, M. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e153 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Fibroblast growth factor 21 serum concentrations in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (DM2). (August 2018) Authors: Walus-miarka, M.; Idzior-Walus, B.; Kapusta, M.; Trojak, A.; Miarka, P.; Malecki, M.T. Journal: Atherosclerosis Issue: Volume 275(2018) Page Start: e151 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗